Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 20/20 | 0.54 |
| ▸ | PPARA | Q07869 | 19/20 | 0.54 |
| ▸ | PPARD | Q03181 | 8/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6700737 | 0.98 | PPARA (0.55) | PPARGPPARAPPARD | |
| SCHEMBL5104761 | 0.94 | PPARG (0.54) | PPARGPPARAPPARD | |
| SCHEMBL5125989 | 0.93 | PPARG (0.55) | PPARGPPARAPPARD | |
| SCHEMBL5106406 | 0.92 | PPARA (0.65) | PPARGPPARAPPARD | |
| SCHEMBL14431465 | 0.92 | PPARG (0.56) | PPARGPPARAPPARD | |
| SCHEMBL6699972 | 0.91 | PPARA (0.66) | PPARGPPARAPPARD | |
| SCHEMBL5110786 | 0.90 | PPARA (0.52) | PPARGPPARA | |
| SCHEMBL5111265 | 0.89 | PPARG (0.63) | PPARGPPARAPPARD | |
| SCHEMBL5099284 | 0.86 | PPARG (0.65) | PPARGPPARAPPARD | |
| SCHEMBL6696851 | 0.86 | PPARA (0.62) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080146631-A1 | OXAZOLYL-ARYLOXYACETIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | BROOKS DAWN ALISA | 2008-06-19 | — | — | US | disclosed |
| US-7351728-B2 | Oxazolyl-aryloxyacetic acid derivatives and their use as PPAR agonists | ELI LILLY AND COMPANY (US) | 2008-04-01 | — | — | US | disclosed |
| EP-1313715-B1 | OXAZOLYL-ARYLOXYACETIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | LILLY CO ELI (US) | 2007-08-01 | — | — | EP | disclosed |
| US-6982278-B2 | Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists | ELI LILLY AND COMPANY (US) | 2006-01-03 | — | — | US | disclosed |
| US-20050250825-A1 | Oxazolyl-aryloxyacetic acid derivatives and their use as PPAR agonists | BROOKS DAWN A | 2005-11-10 | — | — | US | disclosed |
| US-20040024034-A1 | Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists | BROOKS DAWN ALISA (US) | 2004-02-05 | — | — | US | disclosed |
| EP-1313715-A1 | OXAZOLYL-ARYLOXYACETIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | ELI LILLY AND COMPANY (US) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002018355-A1 | OXAZOLYL-ARYLOXYACETIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | ELI LILLY AND COMPANY (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250825-A1 | Oxazolyl-aryloxyacetic acid derivatives and their use as PPAR agonists | PPARA, PPARG, PPARD | PPARG 2/4885PPARA 1/4885PPARD 3/4885 |
| US-20040024034-A1 | Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists | PPARA, PPARG, PPARD | PPARG 2/4885PPARA 1/4885PPARD 3/4885 |
| US-20080146631-A1 | OXAZOLYL-ARYLOXYACETIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | PPARA, PPARG, PPARD | PPARG 2/4885PPARA 1/4885PPARD 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.